Developer docs
API playgroundTry for free, no card

Search company profiles

BackBeat Medical

Full company profile

uuid0003txl

Namestring
BackBeat Medical
Legal namestring
BackBeat Medical Inc.
Company typeenum
Private
Founded yearint
2010
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew Hope, United States
HQ citystring
New Hope
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
cardiac neuromodulation therapy, hypertension treatment devices, novel pacing algorithms, cardiovascular medical devices, therapeutic device development
Industry2 codes
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAC
Cardiac Rhythm Management (Pacemakers, ICDs, CRT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cardiovascular Medical Devices
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BackBeat Medical develops BackBeat® Cardiac Neuromodulation Therapy (CNT), a therapeutic medical device that uses novel pacing algorithms to treat hypertension through cardiac neuromodulation. The therapy offers a non-pharmacological interventional approach to blood pressure management by modulating cardiac activity with proprietary pacing patterns.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1BackBeat® Cardiac Neuromodulation Therapy (CNT)
CategoryCardiovascular therapeutic medical device
Partnership1 partner
TypeStrategic or Co-development Partner
Description

BackBeat Medical is now a wholly-owned subsidiary of Orchestra BioMed, Inc., a therapeutic device company focused on the development and commercialization of high impact, data-driven, transformational solutions for targeted high value unmet medical needs. The BackBeat Cardiac Neuromodulation Therapy (CNT) is one of Orchestra BioMed's leading products.

Peers10 records
TypeDirect peer
Description

Developer of the Barostim baroreflex activation therapy system, an implanted neuromodulation device for heart failure and resistant hypertension. Closely comparable mechanism (electrical neuromodulation) and target indication.

TypeBroad incumbent
Description

Markets the Symplicity renal denervation system for hypertension, the most clinically advanced non-pharmacological alternative to CNT. Comparable as a large incumbent with overlapping device-based hypertension strategy and deep cardiac rhythm management infrastructure.

TypeDirect peer
Description

Developer of the Paradise ultrasound renal denervation system for hypertension. Most directly comparable as a device-based neuromodulation company pursuing durable blood-pressure reduction through an interventional approach.

TypeRegional player
Description

Cardiac rhythm management device manufacturer with significant European presence. Comparable as a pacemaker/ICD manufacturer whose pacing platform and algorithm capabilities are adjacent to CNT's pacing-based neuromodulation therapy.

TypeBroad incumbent
Description

Major cardiac rhythm management and interventional cardiology incumbent with established pacing platforms. Comparable both as a potential CNT delivery platform partner and as a competitor in adjacent neuromodulation and CRM categories.

6Abbott
TypeBroad incumbent
Description

Operates one of the largest cardiac rhythm management businesses globally. Comparable as a pacing-platform incumbent whose device architecture and algorithm roadmap could either compete with or enable CNT-like pacing therapies.

7Kona Medical
TypeEmerging player
Description

Developer of externally delivered focused ultrasound for renal denervation in hypertension. Comparable as a non-implant neuromodulation approach to drug-resistant hypertension, addressing the same unmet need as CNT.

TypeEmerging player
Description

Develops a chemical (alcohol-mediated) renal denervation therapy for hypertension. Comparable as an early-stage device-based hypertension therapy pursuing durable BP reduction via a catheter-delivered neuromodulation approach.

TypeEmerging player
Description

Developer of the ROX Coupler, an interventional device creating an arteriovenous fistula for treatment-resistant hypertension. Comparable as a device-based alternative therapy for the same patient population CNT targets.

TypeBroad incumbent
Description

Parent company of BackBeat Medical and developer of multiple therapeutic device programs including CNT. Directly comparable as the strategic vehicle commercializing BackBeat's technology and operating in adjacent cardiovascular device categories.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BackBeat Medical

Cardiovascular Medical Devicesbackbeatmedical.com

BackBeat Medical firmographics

Firmographics
Name
BackBeat Medical
Legal name
BackBeat Medical Inc.
Website
https://backbeatmedical.com
Company type
Private
Founded year
2010
Operating status
Acquired
Headcount range
1–10 employees
Ownership category
akta.pro rank

BackBeat Medical industry classification

Industry
Product category
Cardiovascular Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAC
Cardiac Rhythm Management (Pacemakers, ICDs, CRT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Cardiac neuromodulation therapy
  • Hypertension treatment devices
  • Novel pacing algorithms
  • Cardiovascular medical devices
  • Therapeutic device development

Where BackBeat Medical is headquartered

Location

Headquarters

HQ city
New Hope
HQ country
United States
HQ region
North America

Markets served

BackBeat Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

BackBeat Medical product offering

Product offering

Core offering

BackBeat Medical develops BackBeat® Cardiac Neuromodulation Therapy (CNT), a therapeutic medical device that uses novel pacing algorithms to treat hypertension through cardiac neuromodulation. The therapy offers a non-pharmacological interventional approach to blood pressure management by modulating cardiac activity with proprietary pacing patterns.

Differentiator

Problem solved

Functional benefit

Products and services

  • BackBeat® Cardiac Neuromodulation Therapy (CNT)

Companies that use BackBeat Medical

Customer profile

Segments1 record

Ideal customer profiles1 record

BackBeat Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

BackBeat Medical partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Orchestra BioMed, Inc.Strategic or Co-development PartnerBackBeat Medical is now a wholly-owned subsidiary of Orchestra BioMed, Inc., a therapeutic device company focused on the development and commercialization of high impact, data-driven, transformational solutions for targeted high value unmet medical needs. The BackBeat Cardiac Neuromodulation Therapy (CNT) is one of Orchestra BioMed's leading products.

BackBeat Medical competitors and assessment

Company assessment

Direct peers

  • CVRx: Developer of the Barostim baroreflex activation therapy system, an implanted neuromodulation device for heart failure and resistant hypertension. Closely comparable mechanism (electrical neuromodulation) and target indication.
  • ReCor Medical: Developer of the Paradise ultrasound renal denervation system for hypertension. Most directly comparable as a device-based neuromodulation company pursuing durable blood-pressure reduction through an interventional approach.

Broad incumbents

  • Medtronic: Markets the Symplicity renal denervation system for hypertension, the most clinically advanced non-pharmacological alternative to CNT. Comparable as a large incumbent with overlapping device-based hypertension strategy and deep cardiac rhythm management infrastructure.
  • Boston Scientific: Major cardiac rhythm management and interventional cardiology incumbent with established pacing platforms. Comparable both as a potential CNT delivery platform partner and as a competitor in adjacent neuromodulation and CRM categories.
  • Abbott: Operates one of the largest cardiac rhythm management businesses globally. Comparable as a pacing-platform incumbent whose device architecture and algorithm roadmap could either compete with or enable CNT-like pacing therapies.
  • Orchestra BioMed: Parent company of BackBeat Medical and developer of multiple therapeutic device programs including CNT. Directly comparable as the strategic vehicle commercializing BackBeat's technology and operating in adjacent cardiovascular device categories.

Regional players

  • Biotronik: Cardiac rhythm management device manufacturer with significant European presence. Comparable as a pacemaker/ICD manufacturer whose pacing platform and algorithm capabilities are adjacent to CNT's pacing-based neuromodulation therapy.

Emerging players

  • Kona Medical: Developer of externally delivered focused ultrasound for renal denervation in hypertension. Comparable as a non-implant neuromodulation approach to drug-resistant hypertension, addressing the same unmet need as CNT.
  • Ablative Solutions: Develops a chemical (alcohol-mediated) renal denervation therapy for hypertension. Comparable as an early-stage device-based hypertension therapy pursuing durable BP reduction via a catheter-delivered neuromodulation approach.
  • Rox Medical: Developer of the ROX Coupler, an interventional device creating an arteriovenous fistula for treatment-resistant hypertension. Comparable as a device-based alternative therapy for the same patient population CNT targets.

Market position

Customer concentration

BackBeat Medical social profiles

Digital presence

BackBeat Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BackBeat Medical leadership team

Management profile

Number of profiles

Profiles2 records

BackBeat Medical funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BackBeat Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BackBeat Medical

What does BackBeat Medical do?

BackBeat Medical develops BackBeat® Cardiac Neuromodulation Therapy (CNT), a therapeutic medical device that uses novel pacing algorithms to treat hypertension through cardiac neuromodulation. The therapy offers a non-pharmacological interventional approach to blood pressure management by modulating cardiac activity with proprietary pacing patterns.

Is BackBeat Medical a public or private company?

BackBeat Medical is a private company. It is classified as corporate owned and is currently acquired.

When was BackBeat Medical founded?

BackBeat Medical was founded in 2010. It employs 1 to 10 people.

Where is BackBeat Medical based?

BackBeat Medical is headquartered in New Hope, United States, in the North America region.

Who are BackBeat Medical's main competitors?

Direct peers on record are CVRx and ReCor Medical. Broad incumbents are Medtronic, Boston Scientific, Abbott and Orchestra BioMed. Biotronik is listed as a regional player. Emerging players are Kona Medical, Ablative Solutions and Rox Medical.

Does BackBeat Medical have an API?

No public API is recorded for BackBeat Medical.

What industry is BackBeat Medical in?

BackBeat Medical's product category is Cardiovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation), with a secondary code of HLAHAFAC, Cardiac Rhythm Management (Pacemakers, ICDs, CRT). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireClinical Data for BackBeat Medical's Programmable Hypertension Control Therapy to Be Presented at ICI Meeting 2016BackBeat Medical Inc. announced that clinical data from its first-in-man study of the Programmable Hypertension Control (PHC) therapy will be presented at the ICI Meeting 2016 in Tel Aviv, Israel on December 5. The presentation will feature two-year follow-up data from patients using the company's Moderato pacemaker, showing average blood pressure reductions of 24 mmHg from baseline (in-office) and 14 mmHg (24-hour ambulatory). Dr. Yuval Mika, CEO and co-founder, will deliver the presentation during the Technology Parade I - Devices session.PR NewswireBackBeat Medical to Present at the 28th Annual Piper Jaffray Healthcare ConferenceBackBeat Medical Inc. announced that David Hochman, President and Co-Founder, will present at the 28th Annual Piper Jaffray Healthcare Conference on November 29, 2016, at the Lotte New York Palace in New York. The presentation will provide an overview of the company's novel cardiac stimulation-based therapies for hypertension and heart failure, including clinical results from its PHC therapy demonstrating average blood pressure reductions of 24 mmHg from baseline in-office measurements and 14 mmHg in 24-hour ambulatory measurements.PR NewswireBackBeat Medical Clinical Data Presented at TCT 2016 Show Continued Reduction in Blood Pressure Over One Year with Cardiac Pacing-Based Hypertension TreatmentBackBeat Medical Inc. presented clinical data at the TCT 2016 conference in Washington, D.C., demonstrating that its Programmable Hypertension Control (PHC) therapy incorporated into the Moderato pacemaker achieved sustained blood pressure reduction over one year, with an average systolic reduction of 13.9 mmHg (p<0.001). Extended follow-up data showed maintained effects at 18 and 24 months with average reductions of 18.7 and 19.7 mmHg respectively. The company is pursuing regulatory approval in Europe and currently enrolling a 170-patient randomized, double-blind study to further validate the therapy.PR NewswireClinical Data for BackBeat Medical's Programmable Hypertension Control Therapy to Be Presented at TCT 2016BackBeat Medical Inc. announced that clinical data from its first-in-man study of a Programmable Hypertension Control (PHC) therapy will be presented at the TCT 2016 conference in Washington. The presentation, led by Dr. Karl-Heinz Kuck, details results from a dual-chamber pacemaker incorporating BackBeat's proprietary PHC algorithm for treating hypertension. Additionally, co-founder Darren Sherman will present the technology in the Shark Tank Innovation Competition during the same event.MedCity NewsCan you kill two birds (slow heart beat and hypertension) with one stone (pacemaker)?BackBeat Medical presented results of a small study showing its pacemaker-based hypertension algorithm reduced blood pressure by 11 mmHg immediately and 20 mmHg after 12 months. The company plans a pivotal U.S. trial before early 2018, aiming for CE Mark and commercialization.PR NewswireClinical Data Presented at ESC Congress Show BackBeat Medical's Cardiac Pacing-Based Treatment for Hypertension Produces Significant, Sustained Reductions in Blood PressureBackBeat Medical Inc. presented clinical trial data at the ESC Congress 2016 in Rome demonstrating that its Programmable Hypertension Control (PHC) therapy significantly reduced blood pressure in hypertensive pacemaker patients, with 24-hour ambulatory systolic pressure decreasing by 11 mmHg immediately after activation and 14 mmHg from baseline after three months. The company also announced enrollment has begun in a 170-patient randomized double-blind study and that it is pursuing European regulatory approval for the therapy. CEO Yuval Mika stated that PHC therapy represents a potential new field of hypertension treatment leveraging the existing pacemaker market, with sustained reductions of up to 21 mmHg observed at 24 months in study participants.